Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
EBITDA as a percentage of revenue
Latest
-12.38%
↑ 93% vs avg
Percentile
P80
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
-180.02%
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | -12.38% | +78.7% |
| 2024 | -58.20% | +92.3% |
| 2023 | -754.69% | -226.3% |
| 2022 | -231.27% | -879.8% |
| 2021 | -23.60% | - |
| 2020 | 0.00% | - |